We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+27.23%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$157M
AUM Growth
+$11.1M
Cap. Flow
-$4.85M
Cap. Flow %
-3.1%
Top 10 Hldgs %
84.67%
Holding
43
New
2
Increased
3
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$3.23M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.29M
3
EXAI
Exscientia Plc American Depositary Shares
EXAI
+$836K
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$198K
5
RLMD icon
Relmada Therapeutics
RLMD
+$156K

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$6.1M
2
SNOW icon
Snowflake
SNOW
+$2.67M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$1.65M
4
TRDA icon
Entrada Therapeutics
TRDA
+$406K
5
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$383K

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$54.4M 34.69%
241,639
+15,951
+7% +$3.23M
ILMN icon
2
Illumina
ILMN
$31B
$22.7M 14.51%
122,533
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.02B
$22.6M 14.44%
510,978
-125,000
-20% -$6.1M
EXAI
4
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$7M 4.47%
853,050
+82,850
+11% +$836K
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
$6.44M 4.11%
47,096
– –
SLGC
6
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.92M 3.14%
1,696,558
– –
RANI icon
7
Rani Therapeutics
RANI
$87.3M
$4.73M 3.02%
493,584
– –
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.1B
$4.13M 2.64%
114,380
– –
EAR
9
DELISTED
Eargo, Inc. Common Stock
EAR
$3.03M 1.93%
144,336
– –
REPL icon
10
Replimune Group
REPL
$920M
$2.68M 1.71%
155,199
– –
INCY icon
11
Incyte
INCY
$24.3B
$2.29M 1.46%
34,391
– –
KDNY
12
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.24M 1.43%
+113,950
New +$2.29M
TRDA icon
13
Entrada Therapeutics
TRDA
$262M
$2.23M 1.42%
141,593
-31,989
-18% -$406K
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.01M 1.28%
111,984
-125,500
-53% -$1.65M
CCXI
15
DELISTED
ChemoCentryx, Inc.
CCXI
$1.85M 1.18%
35,830
– –
BOLT icon
16
Bolt Biotherapeutics
BOLT
$7.65M
$1.73M 1.1%
58,348
– –
ONC
17
BeOne Medicines Ltd
ONC
$32.7B
$1.62M 1.03%
12,022
– –
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$1.14M 0.73%
78,720
– –
GRTX
19
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.07M 0.68%
613,223
– –
STSA
20
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$1.07M 0.68%
177,900
+35,000
+24% +$198K
EXEL icon
21
Exelixis
EXEL
$13.4B
$1.01M 0.64%
64,200
– –
PACB icon
22
Pacific Biosciences
PACB
$441M
$841K 0.54%
144,840
– –
DBVT
23
DBV Technologies
DBVT
$798M
$657K 0.42%
37,095
– –
TSVT
24
DELISTED
2seventy bio
TSVT
$586K 0.37%
40,273
– –
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$11.6B
$518K 0.33%
6,115
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q3 2022 Portfolio in Review

As of Q3 2022, Nan Fung Group Holdings held 43 positions worth $157M, up 7.6% from $146M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Nan Fung Group Holdings withdrew a net $4.85M in Q3 2022, closing 4 positions and reducing 4 holdings. Its most notable exit was Snowflake, an estimated $2.67M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Technology.

Against the trend, Nan Fung Group Holdings opened a new position in Chinook Therapeutics, Inc. Common Stock worth $2.24M.

  • Nan Fung Group Holdings's largest Q3 2022 buy was Chinook Therapeutics, Inc. Common Stock: 113,950 shares worth $2.24M.
  • Nan Fung Group Holdings added most to Karuna Therapeutics, Inc. Common Stock in Q3 2022, an estimated $3.23M increase.
  • Nan Fung Group Holdings's biggest Q3 2022 reduction was Harmony Biosciences, cutting an estimated $6.1M.
  • Nan Fung Group Holdings fully exited Snowflake in Q3 2022, selling an estimated $2.67M.
  • Nan Fung Group Holdings's ten largest holdings make up 85% of its $157M portfolio in Q3 2022.
  • Nan Fung Group Holdings opened 2 new positions and closed 4 in Q3 2022.
  • Nan Fung Group Holdings's portfolio value rose 7.6% quarter-over-quarter to $157M.

Based on Nan Fung Group Holdings's 13F filing for Q3 2022, filed 10 Nov 2022.